AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
Researchers have found that repetitive transcranial magnetic stimulation (rTMS) can efficiently reduce the symptoms of ...
The Sydney Bondi Junction mall knife attacker fatally stabbed six people and injured 10 others in just three minutes, an ...
Hosted on MSN13h
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trialsAbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...
Zacks.com on MSN12h
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
In 2014, Anderson died after her family repeatedly called 911 for mental health assistance. Anderson had bipolar disorder and ...
Some American clinics claim they can ‘rank’ embryos for IVF using a genetic screening system which is illegal in the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback